Rehovot/Munich, February 11, 2026. Evogene Ltd. (Nasdaq/TASE: EVGN), Systasy Bioscience GmbH, and LMU University Hospital Munich (in cooperation with the German Center for Children's Health) have agreed on an international collaboration to develop novel therapies for hyperinflammatory diseases caused by dysregulated neutrophil activity – including inflammatory bowel diseases (IBD). The project is funded by a pan-European EUREKA grant and also involves the Weizmann Institute of Science (Rehovot).
Neutrophils play a central role in inflammatory responses and tissue damage but are not specifically targeted by existing therapies. The team led by Prof. Christoph Klein (LMU University Hospital Munich) is using insights from a rare genetic immunodeficiency with reduced neutrophil counts to develop new approaches that modulate excessive neutrophil-mediated inflammation – without the risks associated with strong immunosuppression.
Contribution of the Partners:
- Evogene leads drug discovery with its ChemPass AI™ platform for generative design of small molecules.
- Systasy is expanding its PathwayProfiler™ technology with DNA barcoding for high-parallel functional profiling in patient-based iPSC neutrophil models.
- LMU University Hospital Munich (Prof. Klein) is validating lead compounds in human in vitro models and driving translation and biomarker development.
- The Weizmann Institute supports high-throughput experiments and validation of AI designs.
The collaboration aims for safe, selective, and effective treatments that address a high unmet need.
